Arsenic trioxide has recently been reported to be successful in the treatment of promyelocytic leukemia. Several concerns about the use of this toxic agent are currently reducing its potential clinical use even in severely ill patients. In this report we describe the results achieved by As 2 O 3 with all-trans retinoic acid in a patient suffering from secondary, relapsed, resistant promyelocytic leukemia. Several complications, including sepsis and an extensive area of skin necrosis, did not allow us to treat the patient further with chemotherapy. With As 2 O 3 and ATRA therapy, the patient obtained a complete molecular remission without any significant toxicity and, subsequently, it was possible to perform a bone marrow autograft in a state of complete remission. Keywords: arsenic; acute promyelocytic leukemia; bone marrow transplantation; all-trans retinoic acid; chemoresistance Acute promyelocytic leukaemia (APL) represents a welldefined subset of acute myeloblastic leukemia (AML), characterized by the typical promyelocytic morphology of blast cells, 1,2 and by coagulopathy. 3 Moreover a typical t(15;17) translocation is present in the large majority of cases, the other two reported cytogenetic abnormalities, t(11;17) and t(5;17), being extremely rare. 4 t(15;17) involves the retinoic acid receptor-␣ (RAR␣) gene on chromosome 17 and the PML gene on chromosome 15 giving rise to the chimeric gene PML/RAR␣. 5 In the recent past, it has been reported that APL shows a remarkable sensitivity to chemotherapy and complete remission (CR) rates of 75% to 80% have been observed. 6 Moreover, APL is very sensitive to anthracyclines used as single agents. 7, 8 Since 1988 9 it has been shown and then consistently confirmed 10 that all-trans retinoic acid (ATRA) induces about 90% CR in newly diagnosed and first relapsed APL. Despite this high remission rate, virtually all patients who achieve CR with ATRA and are maintained on ATRA Correspondence: M Petrini, Divisione di Ematologia-Dipartimento di Oncologia, Via Rome, 67, 56100 Pisa Italy Received 11 January 1999; accepted 8 March 1999 alone are reported to relapse within a few months.
alone are reported to relapse within a few months. [11] [12] [13] In order to reduce this relapse rate, ATRA has been successfully combined with intensive chemotherapy. 14, 15 In a recent report 16 the association of ATRA and idarubicin as induction protocol was found to induce in 318 evaluable patients 94.5% hematological remissions. It has been reported that 60% of cases evaluated by RT-PCR at remission are negative at the end of induction therapy before consolidation. In spite of these fascinating results, a portion of these PCR negative patients will eventually relapse. The role of maintenance therapy and of bone marrow transplantation is still unresolved, especially considering that some groups of patients are still at relatively high risk of relapse (about 40%). 6 Recently, the use of arsenic trioxide (As 2 O 3 ) in the treatment of APL patients in relapse after ATRA induction and chemotherapy has been reported to result in maintained complete remission. In these patients clinical CR was achieved in more than 90% of cases. 17 This agent appears to offer new prospects in relapsed APL, but it appears evident that therapeutic options in relapsed, resistant and even in CR (both hematological and molecular) require further evaluation. We report an intriguing case of secondary APL treated at our institution.
Case report
A 30-year-old man with Burkitt's lymphoma was treated at our institution in March 1994 according to the CODOX-IVAC protocol, 18 reaching complete remission. While still being followed up, in December 1996 he was found to have APL. Secondary APL is a relatively rare disease and does not appear to have a different prognosis from the primary disease. The patient was not suffering from primary or acquired immunodeficiency.
Peripheral blood counts showed severe anemia (Hb 7.7 g/dl), platelet reduction (25 × 10 9 /l) and increased leukocytes (37.6 × 10 9 /l), with 60% of blasts on the differential count. Bone marrow examination showed almost complete replacement by blasts represented by highly abnormal, hypergranular promyelocytes (Figure 1a ). Frequent Aüer rods were detected, often in faggots. Blasts were strongly positive for myeloperoxidase and proved to be reactive for CD33 and CD13, but not for CD34. Cells were shown to The patient was treated with high doses of idarubicin and ATRA as induction therapy, and with Ara-C plus idarubicin or mitoxantrone for three consolidation courses in accordance with the AIDA protocol. 15 He achieved complete hematological and molecular remission after induction therapy. At the end of the treatment protocol, complete remission was maintained by ATRA 45 mg/m 2 for 15 days every 3 months. In this phase, bone marrow aspiration was performed and stored in liquid nitrogen in order to allow an autograft in the event of a relapse.
In spite of a strict follow-up including morphological and molecular evaluation of the bone marrow, the patient relapsed 13 months after achieving first complete remission, and 9 months after the end of consolidation therapy. Clinical relapse appeared 100 days after the last bone marrow examination confirming complete remission. He developed fever, asthenia and low blood cell counts. Bone marrow examination showed an increased number of atypical promyelocytes with morphological features comparable to those found at the first diagnosis ( Figure 1b) ; t (15;17) and PML/RAR␣ (bcr3) were also detected at this time.
Immunophenotyping of blasts was comparable to that found at diagnosis. MDR1 expression was confirmed in this phase by RT-PCR. No coagulopathy was detected. The patient was treated again with the induction schedule of the AIDA protocol, without success. Twenty-five days after the end of chemotherapy, he had a reduction in leukocytes (1.03 × 10 9 /l, promyelocytes 95%), erythrocytes (Hb 8.1 g/dl), and platelets (17 × 10 9 /l). ATRA was continued. In this phase, severe sepsis with Pseudomonas aeruginosa occurred. A large (8 cm diameter), deep necrotic area around the exit site of the central venous catheter developed. The serious, potentially lethal clinical status did not allow any further attempt to treat the patient with chemotherapeutic agents. After supportive therapy, the necrotic area was surgically removed and As 2 O 3 therapy was added to the ATRA schedule which had started more than 45 days before. As 2 O 3 was administered on compassionate grounds, out of any established trial, on the responsibility of researchers after obtaining informed consent from the patient and his relatives. The local ethical committee was informed.
One hundred mg As 2 O 3 powder purchased for laboratory use from Carlo Erba (Italy), 99.8% pure, was suspended in 100 ml sterile H 2 O and boiled for 5 min. Then three drops of HC1 38% were added and the solution was stored at room temperature for 24 h. At this time the powder appeared to be completely dissolved and the solution was filtered through a sterile 0.22 m filter and stored as a bulk solution at room temperature. In accordance with a previous paper, 17 10 ml of this solution was added to 500 ml of 5% glucose and administered i.v. over 2 h once a day for 20 consecutive days. Besides morphological, cytogenetic and molecular evidence of promyelocytic leukemia in the bone marrow, base line parameters showed: anemia (Hb 6.6 g/dl), leukopenia (WBC 1. No clinical or chemical adverse events were recorded. The patient was successfully given a skin autograft to repair the surgically unresolved wound from the removal of the area of necrosis reported above. Two months later, without further therapy, complete clinical and hematological recovery occurred (Hb 12.5 g/dl; WBC 8.7 × 10 9 /l; PLT 322 × 10 9 /l) and the patient successfully underwent a bone marrow autotransplant. One hundred days later he is still well in a state of both cytological and molecular complete remission.
Discussion
The clinical use of arsenic trioxide has recently been reported to be successful 17, 18 and confirmed to be efficacious in relapsed APL. 19 Several questions about the use of As 2 O 3 are unresolved concerning its role in resistant disease, drug availability and toxicity, possible association with ATRA, thus limiting its clinical use. Faced with a patient with secondary APL relapsed and resistant to ATRA + chemotherapy, we decided to treat him with ATRA and As 2 O 3 . In spite of his very critical clinical status, he achieved complete remission and was able to successfully tolerate an autograft. No toxicity from this therapy was detected. The rise in WBC and PLT was fast and achieved without any cytotoxic drugs. These observations strongly support the reported hypothesis of a differentiating activity of arsenic. Arsenic trioxide has been shown to induce cell line apoptosis and degradation of the oncogenic PML/RAR␣ fusion protein. This PML/RAR␣ degradation is significantly induced even in ATRA-resistant cell lines. 20 We are not able to clarify whether As 2 O 3 activity is mediated, in this case, by reversing ATRA resistance or if it is independent of ATRA. However, in this case neither the reported myelocyte-like cells, nor degenerative cells 21 were detected after 2 to 3 weeks of arsenic infusion probably as a result of partial in vivo differentiation. The WBC increase and morphological modifications to normal peripheral blood cell counts were characterized by a progressive reduction in blast cells and an increase in normal cells after the first week of therapy. In this phase, only a few circulating polychromatic and pyknotic erythroblasts appeared. Differences between the reported morphological features and our results might be accounted for by the simultaneous administration of ATRA and arsenic.
In this case, a complete, stable molecular remission was achieved and this might again be related to the ATRA association even if the patient was proved to be ATRAresistant. On these clinical grounds, the action mechanism of the arsenic-ATRA association appears to be related to differentiation rather to apoptosis induction. In this case, no modifications of bcl2 were detected on bone marrow aspirate, assayed by RT-PCR (data not shown). Recently, strong support to the concurrent use of ATRA and As 2 O 3 has been suggested by the paper from Wang et al, 22 showing that As 2 O 3 may reduce PML-RAR␣ expression, thus increasing the ATRA effect.
In conclusion, administration of As 2 O 3 and ATRA induced complete remission without toxicity in this patient allowing us to successfully perform a bone marrow autograft. This report appears to extend a previous longer paper confirming the potentially curative role of arsenic even in severely ill, resistant patients.
